These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29915524)

  • 41. Preliminary report of transmitted drug resistance to integrase strand chain transfer inhibitors in treatment-naïve HIV infected patients.
    Ferrer P; Ramos V; Puente MI; Afani A
    Diagn Microbiol Infect Dis; 2023 Dec; 107(4):116083. PubMed ID: 37778156
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs.
    Kirichenko A; Lapovok I; Baryshev P; van de Vijver DAMC; van Kampen JJA; Boucher CAB; Paraskevis D; Kireev D
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32752001
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Variability of the HIV-1 3' polypurine tract (3'PPT) region and implication in integrase inhibitor resistance.
    Malet I; Delelis O; Nguyen T; Leducq V; Abdi B; Morand-Joubert L; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2019 Dec; 74(12):3440-3444. PubMed ID: 31730161
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV-1 integrase drug-resistance mutations in Iranian treatment-experienced HIV-1-infected patients.
    Marjani A; Bokharaei-Salim F; Jahanbakhshi F; Monavari SH; Esghaei M; Kalantari S; Kiani SJ; Ataei-Pirkooh A; Fakhim A; Keyvani H
    Arch Virol; 2020 Jan; 165(1):115-125. PubMed ID: 31741096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection.
    Ambrosioni J; Nicolás D; Manzardo C; Agüero F; Blanco JL; Mosquera MM; Peñafiel J; Gatell JM; Marcos MA; Miró JM
    J Antimicrob Chemother; 2017 Jan; 72(1):205-209. PubMed ID: 27624569
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice.
    Alteri C; Scutari R; Bertoli A; Armenia D; Gori C; Fabbri G; Mastroianni CM; Cerva C; Cristaudo A; Vicenti I; Bruzzone B; Zazzi M; Andreoni M; Antinori A; Svicher V; Ceccherini-Silberstein F; Perno CF; Santoro MM
    Virus Genes; 2019 Jun; 55(3):290-297. PubMed ID: 30796743
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: findings from a national representative HIV drug resistance survey.
    Kamori D; Barabona G; Rugemalila J; Maokola W; Masoud SS; Mizinduko M; Sabasaba A; Ruhago G; Sambu V; Mushi J; Mgomella GS; Mcollogi JJ; Msafiri F; Mugusi S; Boniface J; Mutagonda R; Mlunde L; Amani D; Mboya E; Mahiti M; Rwebembera A; Ueno T; Pembe A; Njau P; Mutayoba B; Sunguya B
    J Antimicrob Chemother; 2023 Mar; 78(3):779-787. PubMed ID: 36680436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment.
    Pyngottu A; Scherrer AU; Kouyos R; Huber M; Hirsch H; Perreau M; Yerly S; Calmy A; Cavassini M; Stöckle M; Furrer H; Vernazza P; Bernasconi E; Günthard HF;
    Clin Infect Dis; 2021 Oct; 73(7):e2134-e2141. PubMed ID: 33095848
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analyses of HIV-1 integrase gene sequences among treatment-naive patients in the Eastern Cape, South Africa.
    Onoriode Digban T; Chucks Iweriebor B; Chikwelu Obi L; Nwodo U; Ifeanyi Okoh A
    J Med Virol; 2020 Aug; 92(8):1165-1172. PubMed ID: 31889319
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors.
    Andreis S; Basso M; Scaggiante R; Cruciani M; Ferretto R; Manfrin V; Panese S; Rossi MC; Francavilla E; Boldrin C; Alvarez M; Dal Bello F; Mengoli C; Turriziani O; Sarmati L; Antonelli G; Andreoni M; Palù G; Parisi SG
    J Glob Antimicrob Resist; 2017 Sep; 10():106-112. PubMed ID: 28732792
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes.
    Wallis CL; Viana RV; Saravanan S; Silva de Jesus C; Zeh C; Halvas EK; Mellors JW
    J Virol Methods; 2017 Mar; 241():41-45. PubMed ID: 27993614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study.
    Scherrer AU; Yang WL; Kouyos RD; Böni J; Yerly S; Klimkait T; Aubert V; Cavassini M; Battegay M; Hauser C; Calmy A; Schmid P; Bernasconi E; Günthard HF;
    J Infect Dis; 2016 Aug; 214(3):399-402. PubMed ID: 27130429
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention.
    Eshleman SH; Fogel JM; Halvas EK; Piwowar-Manning E; Marzinke MA; Kofron R; Wang Z; Mellors J; McCauley M; Rinehart AR; St Clair M; Adeyeye A; Hinojosa JC; Cabello R; Middelkoop K; Hanscom B; Cohen MS; Grinsztejn B; Landovitz RJ;
    J Infect Dis; 2022 Dec; 226(12):2170-2180. PubMed ID: 36240386
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Consensus HIV-1 subtype A integrase and its raltegravir-resistant variants: design and characterization of the enzymatic properties.
    Shadrina O; Krotova O; Agapkina J; Knyazhanskaya E; Korolev S; Starodubova E; Viklund A; Lukashov V; Magnani M; Medstrand P; Karpov V; Gottikh M; Isaguliants M
    Biochimie; 2014 Jul; 102():92-101. PubMed ID: 24594066
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV Type 1 Integrase Natural Polymorphisms in Viral Variants Circulating in FSU Countries.
    Lapovok I; Laga V; Kazennova E; Bobkova M
    Curr HIV Res; 2017 Nov; 15(5):318-326. PubMed ID: 28814231
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HIV-1 Integrase Resistance among Highly Antiretroviral Experienced Patients from Morocco.
    Alaoui N; El Alaoui MA; El Annaz H; Farissi FZ; Alaoui AS; El Fahime E; Mrani S
    Intervirology; 2019; 62(2):65-71. PubMed ID: 31307042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?
    Koullias Y; Sax PE; Fields NF; Walensky RP; Hyle EP
    Clin Infect Dis; 2017 Oct; 65(8):1274-1281. PubMed ID: 28605418
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Portable Nanopore sequencing solution for next-generation HIV drug resistance testing.
    Park SY; Faraci G; Ganesh K; Dubé MP; Lee HY
    J Clin Virol; 2024 Apr; 171():105639. PubMed ID: 38219684
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
    Lataillade M; Chiarella J; Kozal MJ
    Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.